Clinical Trial Update: Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of a fitness-adapted, pembrolizumab-based regimen for untreated classical Hodgkin lymphoma in patients aged…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Virginia | Conditions: Classical Hodgkin Lymphoma | Phase 2 | Status: RECRUITING